India,
July 2018
Through interviews with the heads of some of India’s leading domestic pharmaceutical companies, this report delves into the biologics, biosimilars and new chemical entities being developed in India and taken abroad; the nation’s hubs of development and innovation, notably the northern state of Gujarat; and how Indian companies have stepped up their quality compliance game following a spate of US FDA warning letters.
Other key topics covered in this report include the startling growth of the contract research and contract manufacturing sectors as pharma companies divest an ever-increasing number of non-core activities; the enduring importance of the domestic market; and how Indian organizations are consolidating their presence abroad through a series of acquisitions and tie-ups with international entities.
Through interviews with the heads of some of India’s leading domestic pharmaceutical companies, this report delves into the biologics, biosimilars and new chemical entities being developed in India and taken abroad; the nation’s hubs of development and innovation, notably the northern state of Gujarat; and how Indian companies have stepped up their quality compliance game following a spate of US FDA warning letters.
Other key topics covered in this report include the startling growth of the contract research and contract manufacturing sectors as pharma companies divest an ever-increasing number of non-core activities; the enduring importance of the domestic market; and how Indian organizations are consolidating their presence abroad through a series of acquisitions and tie-ups with international entities.
